• PMD31- ASSESSING FUNCTIONAL STATUS IN CHILDREN- A REVIEW OF THE CHILDHOOD HAQ FOR NON-ARTHRITIS INDICATIONS

    May 1, 2003, 00:00

  • PNP25- DONEPEZIL VERSUS RIVASTIGMINE UTILIZATION PATTERNS IN A RETROSPECTIVE CLAIMS ANALYSIS

    May 1, 2003, 00:00

  • PMDI8- ECONOMIC EVALUATION IN CLINIC TRIALS- CALCULATING HOSPITALIZARON COSTS FROM CLINIC TRIAL DATA

    May 1, 2003, 00:00

  • PHP48- HOSPITAL PERFORMANCE EVALUATION METHODS IN A REGIONAL MANAGED CARE ORGANIZATION- RANDOM-EFFECT OR FIXED-EFFECT MODEL?

    May 1, 2003, 00:00

  • PGS14- GASTROESOPHAGEAL REFLUX IN INFANTS- IMPACT ON THE QOL OF PARENTS

    May 1, 2003, 00:00

  • PNP13- CAREGIVER HEALTH BENEFITS AND ASSOCIATED REDUCTIONS IN HEALTHCARE COSTS AS A CONSEQUENCE OF TREATING PATIENTS WITH DONEPEZIL

    May 1, 2003, 00:00

  • PPT4- THE ECONOMIC IMPACT OF NOVOSEVEN IN STEM CELL TRANSPLANTATION IN GERMANY AND THE UNITED STATES

    May 1, 2003, 00:00

  • PMD36- JUSTIFYING THE DEVELOPMENT OF A LAY PANEL TO PRODUCE UTILITIES FOR USE IN HEALTH TECHNOLOGY ASSESSMENTS (HTAS)- REVIEW OF CURRENT ISSUES, AND VIEWS OF TECHNOLOGY APPRAISAL COMMITTEE MEMBERS

    May 1, 2003, 00:00

  • PMH22 A NATIONAL ESTIMATE OF INDIRECT COSTS ASSOCIATED WITH ANXIETY DISORDERS

    May 1, 2003, 00:00

  • PMD26- ECONOMIC AND OUTCOMES RESEARCH IN THE REAL WORLD- EVALUATION OF ITS RELEVANCE

    May 1, 2003, 00:00

  • PHD7- THE CONGRUENCE OF SELF-REPORT WITH OTHER MEASURES OF MEDICATION ADHERENCE- A SUMMARY OF THE LITERATURE

    May 1, 2003, 00:00

  • PCHIO- FIVE-YEAR, DIRECT, MEDICAL COSTS AMONG VETERANS ADMINISTRATION PATIENTS WITH CANCER OF THE SIGMOID COLON

    May 1, 2003, 00:00

  • PCN7- CERVICAL CANCER SCREENING IN THE PHILIPPINE SETTING-A COST-EFFECTIVENESS ANALYSIS

    May 1, 2003, 00:00

  • PNP26- VALIDATING THE FACTOR STRUCTURE OF THE DISQ-24 USING STRUCTURAL EQUATION MODELING

    May 1, 2003, 00:00

  • CV1- PATTERNS AND RISK FACTORS FOR NON-COMPLIANCE WITH HMG-COA INHIBITORS IN A MANAGED CARE POPULATION

    May 1, 2003, 00:00

  • PMD35- QUALITY OF LIFE DIFFERENCES IN OLDER ADULTS WITH VARIED COMORBID CONDITIONS

    May 1, 2003, 00:00

  • PIN51- ASSESSING DISEASE-SPECIFIC UTILITY IN RECURRENT GENITAL HERPES (RGH)

    May 1, 2003, 00:00

  • PNP1- GALANTAMINE REDUCES CAREGIVER TIME- AN ANALYSIS OF A NATIONAL SAMPLE OF ALZHEIMERS PATIENTS LIVING IN THE COMMUNITY

    May 1, 2003, 00:00

  • PMH25- SOCIAL ANXIETY DISORDER- EFFECT OF RELAPSE ON COSTS AND QUALITY OF LIFE

    May 1, 2003, 00:00

  • PNP2- IMPACT OF RIVASTIGMINE ON TIME TO FIRST ANTIPSYCHOTIC DRUG USE IN PATIENTS WITH ALZHEIMERS DISEASE

    May 1, 2003, 00:00

  • PMH24- COST-EFFECTIVENESS OF ESCITALOPRAM VERSUS PLACEBO IN RELAPSE PREVENTION IN PATIENTS WITH SOCIAL ANXIETY DISORDER

    May 1, 2003, 00:00

  • DB2- INCOME DISPARITY IN DIFFUSION OF ORAL DIABETES THERAPY 1999-2001

    May 1, 2003, 00:00

  • PCHI I- ESTIMATING THE BUDGET AND HEALTH IMPACTS OF LETROZOLE FOR ADVANCED BREAST CANCER

    May 1, 2003, 00:00

  • PMD34- COMPARISON OF SF-36 SUMMARY AND PREFERENCE-BASED UTILITY SCORES ACROSS GROUPS DIFFERING IN DISEASE SEVERITY- RESULTS FROM THE MEDICARE HEALTH OUTCOMES SURVEY

    May 1, 2003, 00:00

  • PHP I 2- ATTITUDES AS OUTCOMES- UNDERSTANDING THE COMPLEXITY OF THE HEALTHCARE CONSUMER

    May 1, 2003, 00:00

  • PHP29- PREDICTIVE FACTORS OF INPATIENT DRUG COSTS IN A MOTHER-CHILD TEACHING HOSPITAL

    May 1, 2003, 00:00

  • PGS10- TREATMENT PATTERNS AND HEALTH CARE COSTS OF MEBEVERINE-TREATED IBS PATIENTS-A CASE-CONTROL STUDY

    May 1, 2003, 00:00

  • PDB16- COST OF TYPE 2 DIABETES CARE IN AUSTRALIA-THE DIABCOST STUDY

    May 1, 2003, 00:00

  • PDB21- COMPARISON OF HEALTHCARE COSTS FOR REPAGLINIDE, METFORMIN, REPAGLINIDE/METFORMIN, AND GLYBURIDE/METFORMIN WITHIN A MANAGED CARE ORGANIZATION

    May 1, 2003, 00:00

  • PIN13- CHANGES IN ANTIRETROVIRAL (ARV) REGIMENS IN CLINICAL PRACTICE- RESULTS FROM THE STAR (SCHEMAS THERAPEUTIQUESANTIRETROVIRAUX) COHORT

    May 1, 2003, 00:00

  • PHD9- METHODOLOGICAL DESIGNS OUTCOMES OF EFFECTIVENESS STUDIES-A LITERATURE REVIEW

    May 1, 2003, 00:00

  • PCV23- A COST-BENEFIT MODEL FOR PERINDOPRIL IN SECONDARY STROKE PREVENTION

    May 1, 2003, 00:00

  • PMH19- DIFFERENCES AMONG ANTIPSYCHOTICS IN THE TIME TO ALL-CAUSE DRUG DISCONTINUATION- RESULTS FROM A LONGITUDINAL NATURALISTIC STUDY OF SCHIZOPHRENIA

    May 1, 2003, 00:00

  • PDB12- A COMPARISON OF TWO METHODS FOR ESTIMATING HEALTH CARE COSTS OF DIABETES

    May 1, 2003, 00:00

  • PRP26- REVIEW OF QUALITY OF LIFE INSTRUMENTS IN PEDIATRIC ASTHMA

    May 1, 2003, 00:00

  • PRK8- COSTS AND CLINICAL CONSEQUENCES OF ALFUZOSIN AND DOXAZOZIN IN BENIGN PROSTATIC HYPERPLASIA IN UKRAINE

    May 1, 2003, 00:00

  • PIN20- COST-CONSEQUENCES OF INFLUENZA VACCINATION FOR SCHOOL-AGED CHILDREN IN JAPAN

    May 1, 2003, 00:00

  • PIN48- ASSESSING PARENTS PREFERENCE FOR A UNIQUE ANTIBIOTIC DOSE IN THE TREATMENT OF ACUTE OTITIS MEDIA IN CHILDREN BY USING A WILLINGNESS TO PAY METHOD

    May 1, 2003, 00:00

  • PGS2- ASSESSMENT OF THE UTILITY OF SALSALATE WITHIN A COX-2 INHIBITOR CLINICAL USAGE PROTOCOL

    May 1, 2003, 00:00

  • PES7- COST-EFFECTIVENESS ANALYSIS OF CATARACT CONTROL IN 14 WORLD REGIONS

    May 1, 2003, 00:00

  • PD2- A RANDOMIZED CONTROLLED TRIAL OF A DRUG USE REVIEW INTERVENTION FOR ANTIBIOTICS MEDICATIONS FOR OTITIS MEDIA

    May 1, 2003, 00:00

  • PWM12- LONGITUDINAL DIFFERENCES IN PSYCHOLOGICAL ADJUSTMENT FOR MEN WITH ERECTILE DYSFUNCTION- RESULTS FROM EXCEED

    May 1, 2003, 00:00

  • PRP17- THE AVERAGE COSTS OF THE TREATMENT OF ASTHMA EXACERBATIONS IN IN-PATIENT CARE AND HOSPITAL EMERGENCY ROOM IN POLAND

    May 1, 2003, 00:00

  • PRP14- RATES OF ASTHMA-RELATED MEDICAL AND PRESCRIPTION RESOURCE UTILIZATION AND COSTS IN A MEDICAID POPULATION

    May 1, 2003, 00:00

  • PES16- PSORIASIS AND ATOPIC DERMATITIS- CROSS-DESCRIPTION OF PATIENTS QUALITY OF LIFE

    May 1, 2003, 00:00

  • PIN41- PERTUSSIS VACCINATION IN ADOLESCENTS- COSTS AND CONSEQUENCES OF NEW PROPOSED VACCINATION PROGRAMMES IN CANADA

    May 1, 2003, 00:00

  • PCV17- RELATIONSHIP BETWEEN PATIENT BELIEFS ABOUT MEDICATION AND SELF-REPORTED MEDICATION ADHERENCE SIX MONTHS AFTER DISCHARGE FOR ACUTE CORONARY SYNDROMES

    May 1, 2003, 00:00

  • PNP9- COST-EFFECTIVENESS ANALYSIS OF PRAMIPEXOLE IN EARLY PARKINSONS DISEASE

    May 1, 2003, 00:00

  • PCV30- ECONOMIC EVALUATION OF LOSARTAN COMPARED WITH ATENOLOL IN THE TREATMENT OF HYPERTENSION WITH LEFT VENTRICULAR HYPERTROPHY- A COST-MINIMIZATION ANALYISIS BASED ON LIFE STUDY

    May 1, 2003, 00:00

  • PHP30- RATES OF CONTINUATION OF NON FORMULARY MEDICATIONS FOR CHRONIC DISEASE SUFFERERS IN MULTI-TIERED PHARMACY BENEFIT PLANS

    May 1, 2003, 00:00

  • PHP I- COMPLIANCE WITH DRUG TREATMENT IN SWEDEN- AN EPIDEMIOLOGICAL STUDY

    May 1, 2003, 00:00

  • PRK6- A RETROSPECTIVE CLAIMS ANALYSIS OF THE DIRECT COSTS OF STRESS URINARY INCONTINENCE

    May 1, 2003, 00:00

  • PIN30- HOSPITALIZATION EXPENDITURE OF STREPTOCOCCUS PYOGENES-ASSOCIATED CELLULITIS IN THE UNITED STATES

    May 1, 2003, 00:00

  • PCV24- RATES OF HOSPITALIZATIONS FOLLOWING ATHEROTHROMBOTIC STROKE AND ASSOCIATED COSTS

    May 1, 2003, 00:00

  • PHP5I- MEDICAL DEVICE PROBLEMS IN INTENSIVE CARE UNITS- DETECTION, DANGERS, AND DIVERSITY OF TYPES

    May 1, 2003, 00:00

  • PCV22- DISEASE MANAGEMENT REDUCES HEALTHCARE DISPARITIES IN HEART FAILURE PATIENTS

    May 1, 2003, 00:00

  • PHP38- THREE-YEAR PREDICTIVE MODEL OF MEDICAL COST RISK AND METHODOLOGICAL ISSUES RELATED TO AN EXPANDED PHARMACY CLAIMS RISK INDEX

    May 1, 2003, 00:00

  • PNP18- ECONOMIC COMPARISON OF FIVE TRIPTAN STRATEGIES FOR MIGRAINE HEADACHES USING MONTE CARLO SIMULATION

    May 1, 2003, 00:00

  • PNP21- UTILIZATION CHARACTERISTICS OF NARCOTIC ANALGESICS IN WV WORKERS COMPENSATION CLAIMANTS

    May 1, 2003, 00:00

  • PCVI- VALIDATION OF EQUATIONS USED TO PREDICT WARFARIN DOSING DECISIONS

    May 1, 2003, 00:00

  • PCV16- SMOKING DEPENDENCY- AUDIT CARRIED OUT AMONG THE UNDER 25 GROUP

    May 1, 2003, 00:00

  • PRP13- ASSESSING THE COST IMPLICATIONS OF COMBINED PHARMACOTHERAPY IN THE LONG TERM MANAGEMENT OF ASTHMA

    May 1, 2003, 00:00

  • PNP5- COMPARISON OF USING NDC OR ICD CODES TO SELECT PAIN PATIENTS USING DATABASE ANALYSES

    May 1, 2003, 00:00

  • PNP22- PREVALENCE AND MEDICAL CARE COSTS OF BACK PAIN- COMPARISON OF 1996 AND 1999 NATIONAL ESTIMATES

    May 1, 2003, 00:00

  • PMH28- THE IMPACT OF UNRECOGNIZED BIPOLAR DISORDERS FOR PATIENTS TREATED WITH ANTIDEPRESSANT MEDICATIONS

    May 1, 2003, 00:00

  • PCV46- NEW SOFTWARE TO ESTIMATE COSTS AND CALCULATE THE RETURN ON INVESTMENT OF TOBACCO CONTROL PROGRAMS IN A MANAGED CARE SETTING- MEDISAVE SMOKING CESSATION

    May 1, 2003, 00:00

  • PPT5- LONG TERM COST OF ILLNESS STUDY FOR SEVERE HEMOPHILIC CHILDREN IN TORONTO

    May 1, 2003, 00:00

  • PPT3- COST-EFFECTIVENESS OF TRANSFUSING PLATELET COMPONENTS PREPARED WITH PATHOGEN INACTIVATION TREATMENT IN ORTHOPEDIC SURGERY IN THE UNITED STATES

    May 1, 2003, 00:00

  • MDI- AN ECONOMETRIC APPROACH TO GENERATING POPULATION COST ESTIMATES FOR EVENT-TIME DATA-AN EXAMPLE USING RENAL TRANSPLANT GRAFT FAILURE DATA

    May 1, 2003, 00:00

  • PDB27- RISKING HEALTH TO AVOIDING INJECTIONS-STATED PREFERENCES OF TYPE 2 DIABETICS IN THE US AND CANADA

    May 1, 2003, 00:00

  • PNP10- COST-EFFECTIVENESS OF ATOMOXETINE IN THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND ADOLESCENTS

    May 1, 2003, 00:00

  • PWM8- THE LIFETIME MEDICAL COSTS OF WOMEN- CARDIOVASCULAR DISEASE, DIABETES, AND STRESS URINARY INCONTINENCE

    May 1, 2003, 00:00

  • AG 3- A COMPARATIVE COST ANALYSIS OF ALZHEIMERS DISEASE VERSUS VASCULAR DEMENTIA

    May 1, 2003, 00:00

  • PCV26- RATES OF VENOUS THROMBOEMBOLISM AND ASSOCIATED INPATIENT HEALTHCARE RESOURCE USE AMONG PATIENTS UNDERGOING MAJOR ORTHOPEDIC SURGERY IN AN INTEGRATED DELIVERY SYSTEM

    May 1, 2003, 00:00

  • PIN35- ESTIMATING FUTURE HEPATITIS B VIRUS (HBV) DISEASE BURDEN IN THE UNITED STATES USING A DISEASE SIMULATION MODEL

    May 1, 2003, 00:00

  • Costs of Drug Delivery for CHOP, COP/CVP, and Fludarabine- An International Assessment

    Mar 1, 2003, 00:00

  • Rational Formulary Decision Making- Is Drug Classification Rational?

    Mar 1, 2003, 00:00

  • Additional Considerations in Longitudinal Database Research

    Mar 1, 2003, 00:00

  • Indirect Costs of Respiratory Syncytial Virus Hospitalizations- A Commentary

    Mar 1, 2003, 00:00

  • Oseltamivir for Treatment of Influenza in Healthy Adults- Pooled Trial Evidence and Cost-Effectiveness Model for Canada

    Mar 1, 2003, 00:00

  • Cost-Effectiveness of Enoxaparin as Thromboprophylaxis in Acutely Ill Medical Patients in Spain

    Mar 1, 2003, 00:00

  • Economic Comparison of Home-Care-Based versus Hospital-Based Treatment of Chemotherapy-Induced Febrile Neutropenia in Children

    Mar 1, 2003, 00:00

  • Economic Consequences of Renal Dysfunction among Cardiopulmonary Bypass Surgery Patients- A Hospital-Based Perspective

    Mar 1, 2003, 00:00

  • The Use of Claims Databases in Pharmacoeconomic Studies

    Mar 1, 2003, 00:00

  • Economic Costs of Influenza-Related Work Absenteeism

    Mar 1, 2003, 00:00

  • Time and Out-of-Pocket Costs Associated with Respiratory Syncytial Virus Hospitalization of Infants

    Mar 1, 2003, 00:00

  • The Cost-Effectiveness of Acetaminophen, NSAIDs, and Selective COX-2 Inhibitors in the Treatment of Symptomatic Knee Osteoarthritis

    Mar 1, 2003, 00:00

  • A Checklist for Retrospective Database Studies—Report of the ISPOR Task Force on Retrospective Databases

    Mar 1, 2003, 00:00

  • Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation- Report of the ISPOR Task Force on Good Research Practices—Modeling Studies

    Jan 1, 2003, 00:00

  • Functional Status and Somatization as Predictors of Medical Offset in Anxious and Depressed Patients

    Jan 1, 2003, 00:00

  • Drug-Related Problems and Quality of Life in Arthritis and Low Back Pain Sufferers

    Jan 1, 2003, 00:00

  • Computerized Health Information and the Demand for Medical Care

    Jan 1, 2003, 00:00

  • Economic Burden of Long-Term Complications of Deep Vein Thrombosis after Total Hip Replacement Surgery in the United States

    Jan 1, 2003, 00:00

  • How Well Have Practices Followed Guidelines in Prescribing Antihypertensive Drugs- The Role of Health Insurance

    Jan 1, 2003, 00:00

  • Costs of Asthma in a Cohort of Swiss Adults- Associations with Exacerbation Status and Severity

    Jan 1, 2003, 00:00

  • Making Decisions on Technology Availability in the British National Health Service—Why We Need Reliable Models

    Jan 1, 2003, 00:00

  • The ISPOR Good Practice Modeling Principles—A Sensible Approach- Be Transparent, Be Reasonable

    Jan 1, 2003, 00:00

  • Value in Health- “Bridging the Gap” Among Our Disciplines

    Jan 1, 2003, 00:00

  • PIN3 THE TREATMENT OF SEPSIS PATIENTS WITH DROTRECOGIN ALFA (ACTIVATED)-AN ECONOMIC EVALUATION WITH REFERENCE TO ITALY

    Nov 1, 2002, 00:00

  • PES9 COST-EFFECTIVENESS AND COST-UTILITY OF OLOPATADINE IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS (SAC) IN 6 EUROPEAN COUNTRIES

    Nov 1, 2002, 00:00

  • IN1 A BAYESIAN APPROACH TO NET HEALTH BENEFITS-AN ILLUSTRATION AND APPLICATION TO MODELING HIV PREVENTION

    Nov 1, 2002, 00:00

  • PNP11 USE OF THE TOPS AS A PAIN-SPECIFIC HRQOL INSTRUMENT

    Nov 1, 2002, 00:00

  • PCV54 SMOKING CESSATION- RELEVANCE IN THE UNDER 25 GROUP

    Nov 1, 2002, 00:00

  • UT5 COMPARISON OF THE SF6D AND THE EQ5D IN PATIENTS REQUIRING CORONARY REVASCULARISATION

    Nov 1, 2002, 00:00

  • PRP6 ASSESSMENT OF RESPIRATORY DISEASE SEVERITY USING POSTAL QUESTIONNAIRES

    Nov 1, 2002, 00:00

  • PCV37 DOES COMPLIANCE WITH ACE-I, DIGOXIN AND SPIRONOLACTONE INFLUENCE THE TIME TO EVENT IN PATIENTS WITH HEART FAILURE?

    Nov 1, 2002, 00:00

  • PMH11 ANTIPSYCHOTIC MEDICATION PATTERNS IN SCHIZOPHRENIA OUTPATIENTS AND INPATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY- RESULTS FROM THE GEO OBSERVATIONAL STUDY

    Nov 1, 2002, 00:00

  • PNP6 THE BURDEN OF MIGRAINE- BEYOND DIRECT HEALTH CARE COSTS

    Nov 1, 2002, 00:00

  • PMD17 ASSESSMENT OF QUALITY OF LIFE IN CHILDREN- METHOLOGICAL AND CONCEPTUAL ISSUES

    Nov 1, 2002, 00:00

  • PHP19 HEALTH EXPENDITURE FOR THE DURATION OF LAST YEAR OF LIFE IN TAIWAN

    Nov 1, 2002, 00:00

  • PCV50 EVALUATION OF NITRATE PRESCRIPTION PATTERNS AMONG PHYSICIANS FROM DIFFERENT SPECIALITIES IN ISRAEL

    Nov 1, 2002, 00:00

  • PIN34 INITIAL ANTIVIRAL TREATMENT OF CHRONIC HEPATITIS C-A GERMAN HEALTH TECHNOLOGY ASSESSMENT AND DECISION ANALYSIS

    Nov 1, 2002, 00:00

  • PCN8 AVERAGE TOTAL COST OF TREATING ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS IN SPAIN USING VARIOUS CHEMOTHERAPY DOUBLETS

    Nov 1, 2002, 00:00

  • PIN33 FACTORS INFLUENCING INAPPROPRIATE ANTIBIOTIC PRESCRIBING FOR CHILDREN WITH ACUTE BRONCHITIS IN AMBULATORY CARE SETTING

    Nov 1, 2002, 00:00

  • PRP8 QUALITY OF LIFE AND COSTS FOR MODERATE AND SEVERE ASTHMA IN FRANCE

    Nov 1, 2002, 00:00

  • PCV56 ALLOCATION OF RESOURCES BETWEEN SMOKING CESSATION METHODS AND PHARMACEUTICAL TREATMENT OF HYPERCHOLESTEROLEMIA BASED ON COST-EFFECTIVENESS AND THE SOCIAL WELFARE FUNCTION

    Nov 1, 2002, 00:00

  • PHP24 USE OF POLICY MODELING TO PROMOTE INFORMED DECISION MAKING- DEVELOPMENT AND APPLICATION OF THE CANADIAN STROKE POLICY MODEL

    Nov 1, 2002, 00:00

  • POD2 DEVELOPMENT OF ECONOMIC AND OUTCOMES MODEL OF HEMOPHILIA TREATMENT IN LATIN AMERICA AND SOUTH

    Nov 1, 2002, 00:00

  • Author Index, Volume 5

    Nov 1, 2002, 00:00

  • PDB9 DEVELOPMENT AND VALIDATION OF THE INSULIN TREATMENT SATISFACTION QUESTIONNAIRE (ITSQ)

    Nov 1, 2002, 00:00

  • PRP2 3329 STUDY TO EVALUATE HOSPITAL COSTS FOR ACUTE EXACERBATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SPAIN (EPOC-COST STUDY)

    Nov 1, 2002, 00:00

  • PMH14 INCIDENCE OF HYPERLIPIDEMIA DURING TREATMENT OF SCHIZOPHRENIA- FINDINGS IN A CLAIMS DATABASE

    Nov 1, 2002, 00:00

  • PRK6 EVALUATING THE COST OF LONG-ACTING TREATMENTS FOR OVERACTIVE BLADDER

    Nov 1, 2002, 00:00

  • PCV53 INFLUENCE OF THREE HYPERTENSION GUIDELINES ON RATES OF TREATMENT INDICATION

    Nov 1, 2002, 00:00

  • PCV1 AN ECONOMIC EVALUATION OF CLOPIDOGREL IN SECONDARY PREVENTION OF ISCHEMIC EVENTS- HIGH RISK POPULATIONS

    Nov 1, 2002, 00:00

  • PCV32 THE USE OF STATINS IN SECONDARY CARE- EVIDENCE FROM ACTUAL PRACTICE DATA

    Nov 1, 2002, 00:00

  • IN4 DISCOUNTING HEALTH BENEFITS-A NOVEL APPROACH TO ENSURE PROPER VALUING OF VACCINATION STRATEGIES

    Nov 1, 2002, 00:00

  • MD4 CHANGES IN COST-EFFECTIVENESS OVER TIME-THE CASE OF EPOETIN ALFA FOR RENAL REPLACEMENT THERAPY PATIENTS IN THE UK

    Nov 1, 2002, 00:00

  • PIN17 COST-EFFECTIVENESS OF 23-VALENT ANTIPNEUMOCOCCICAL VACCINATION IN CATALONIA (SPAIN)

    Nov 1, 2002, 00:00

  • MD3 VALIDATING A DISEASE MODEL ACCORDING TO CRITERIA OF EVIDENCE BASED MEDICINE

    Nov 1, 2002, 00:00

  • PCV2 PHYSICIAN CHARACTERISTICS OF THE NAVIGATOR TRIAL PREDICT AVERAGE LENGTH OF STAY (ALOS) IN ACUTE CORONARY SYNDROME (ACS)

    Nov 1, 2002, 00:00

  • PCV57 IMPLICATIONS OF TREATMENT GUIDELINES- WHAT STATINS DO WE REALLY NEED?

    Nov 1, 2002, 00:00

  • PMH24 THERE ARE SIGNIFICANT BARRIERS TO THE DIAGNOSIS AND TREATMENT OF ADHD IN EUROPE

    Nov 1, 2002, 00:00

  • PGS12 IRRITABLE BOWEL SYNDROME (IBS) SIGNIFICANTLY AFFECTS PATIENT QUALITY OF LIFE (QOL) AND IS RESPONSIBLE FOR HIGH COSTS IN FRANCE-THE ENCOLI STUDY

    Nov 1, 2002, 00:00

  • PIN7 OUTCOMES AND PATIENT CHARACTERISTICS ASSOCIATED WITH SYSTEMIC FUNGAL INFECTIONS

    Nov 1, 2002, 00:00

  • PES10 PHARMACOECONOMIC EVALUATION OF A NEW TWO COMPOUND OINTMENT (DAIVOBET) AND CALCIPOTRIOL (DAIVONEX) IN THE TREATMENT OF PSORIASIS VULGARIS IN SWEDEN

    Nov 1, 2002, 00:00

  • PWM10 VITAMIN USE AMONG WOMEN OF CHILDBEARING AGE IN US- EVIDENCE FROM THE 1997 MEPS DATA

    Nov 1, 2002, 00:00

  • PMH7 BOTTOM-UP OR TOP-DOWN? IMPACT OF PATIENT SELECTION ON COST-OF-ILLNESS RESULTS

    Nov 1, 2002, 00:00

  • PAR6 ANALYSIS OF CONSUMPTION OF NONSTEROID ANTIINFLAMMATORY DRUGS (GROUP M01) AT NATIONAL LEVEL IN DDD/1000/DAY- 1999-2001

    Nov 1, 2002, 00:00

  • PNP10 ECONOMIC IMPACT OF GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS

    Nov 1, 2002, 00:00

  • CP1 CROSS-CULTURAL DIFFERENCES IN NONADHERENT ATTITUDES

    Nov 1, 2002, 00:00

  • PMD16 ASSESSING QUALITY OF LIFE IN THE ELDERLY- A COMPARISON OF TWO UTILITY MEASURES

    Nov 1, 2002, 00:00

  • PDB5 LONG-TERM CONSEQUENCES FOR THE TREATMENT OF HYPERTENSIVE DIABETES TYPE 2 PATIENTS WITH A FIXED COMBINATION OF AN ACE-INHIBITOR AND NON-DIHYDROPYRIDINE-CALCIUM-CHANNELBLOCKER IN COMPARISON TO OTHER COMBINATION THERAPIES

    Nov 1, 2002, 00:00

  • PIN31 INVESTIGATION INTO THE FEASIBILITY OF DERIVING RELATIVE AND ABSOLUTE UTILITY FROM THE RECURRENT GENITAL HERPES QUALITY OF LIFE QUESTIONNAIRE (RGHQOL)

    Nov 1, 2002, 00:00

  • PWM4 INFLUENCE OF ERECTILE DYSFUNCTION ON HEALTH RELATED QUALITY OF LIFE OF MALE KIDNEY TRANSPLANT PATIENTS ACCORDING TO AGE

    Nov 1, 2002, 00:00

  • PGS16 EVALUATION OF THE USE OF PROTON PUMP INHIBITORS IN A PUBLIC HOSPITAL IN HONG KONG

    Nov 1, 2002, 00:00

  • CN2 ECONOMIC EVALUATION OF NEW POLY-CHEMOTHERAPY REGIMENS AS ALTERNATIVES TO CISPLATIN PLUS PACLITAXEL IN ADVANCED NON-SMALL CELL LUNG CANCER

    Nov 1, 2002, 00:00

  • IN6 PRIMARY CARE PRESCRIBING AND ANTIBIOTIC RESISTANCE-WHAT IS THE ADDED VALUE OF PERSON SPECIFIC DATA ABOUT ANTIBIOTIC PRESCRIBING COMPARED WITH EXISTING, PRACTICE LEVEL INFORMATION?

    Nov 1, 2002, 00:00

  • PCV40 COMORBIDITIES CAUSING INCREASING MORTALITY AT AGES UNDER 65 IN CARDIOVASCULAR DISEASE AND HYPERTENSION

    Nov 1, 2002, 00:00

  • PRP1 INPATIENT AND OBSERVATION UNIT COSTS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Nov 1, 2002, 00:00

  • PCV21 ECONOMIC EVALUATION OF THE PROSPECTIVE RANDOMIZED EVALUATION OF VASCULAR EFFECT OF NORVASC STUDY (PREVENT)-AN ITALIAN CUSTOMIZATION

    Nov 1, 2002, 00:00

  • WP3 WILLINGNESS TO PAY FOR A PHARMACIST INTERVENTION PROGRAM AMONG NONCOMPLIANT DYSLIPIDEMIA PATIENTS

    Nov 1, 2002, 00:00

  • PAR5 DISEASE SEVERITY AND COSTS AMONG PATIENTS STARTING A TREATMENT WITH COX-2 SPECIFIC INHIBITORS VERSUS NSAIDS PATIENTS IN ITALY- QUANTITATIVE ASSESSMENT IN 442 PATIENTS WITH ARTHRITIS

    Nov 1, 2002, 00:00

  • PMD14 THE INFLUENCE OF ILLNESS EXPERIENCE ON HEALTH STATE VALUATIONS

    Nov 1, 2002, 00:00

  • PMH4 ESTIMATING MEDICAL COST REDUCTION IN TREATING SCHIZOPHRENIA WITH CLOZAPINE

    Nov 1, 2002, 00:00

  • PDB7 THE WHO/IDF CARECARD DIABETES AS AN INTERNET-BASED APPROACH FOR QUALITY ASSURANCE IN SWITZERLAND

    Nov 1, 2002, 00:00

  • MD5 SHOULD THE EUROQOL DESCRIPTIVE SYSTEM BE EXTENDED FROM THREE TO FIVE LEVELS? A METHODOLOGICAL STRATEGY WITH AN EMPIRICAL PILOT

    Nov 1, 2002, 00:00

  • PIN21 HOSPITALISATION COSTS FOR YOUNG CHILDREN WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION

    Nov 1, 2002, 00:00

  • PIN36 INCIDENCE OF SEVERE SEPSIS IN THE NETHERLANDS-A POINT PREVALENCE SURVEY

    Nov 1, 2002, 00:00

  • MD2 MEASURING HEALTH IMPACTS ON WORK PERFORMANCE- COMPARING SUBJECTIVE AND OBJECTIVE REPORTS

    Nov 1, 2002, 00:00

  • PCV44 THE IMPACT OF AN EDUCATIONAL INTERVENTION ON MULTIPLE HEALTH REALTED QUALITY OF LIFE MEASURES IN PATIENTS WITH HEART FAILURE (HF)

    Nov 1, 2002, 00:00

  • PCN1 COST ANALYSIS OF HLA-IDENTICAL SIBLING AND VOLUNTARY UNRELATED ALLOGENEIC BONE MARROW AND PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN ADULTS WITH ACUTE MYELOCYTIC LEUKAEMIA OR ACUTE LYMPHOBLASTIC LEUKAEMIA

    Nov 1, 2002, 00:00

  • PMH26 SIMULATING THE COURSE OF SCHIZOPHRENIA USING DISCRETE EVENTS MODELLING

    Nov 1, 2002, 00:00

  • PMD12 GENERIC VERSUS TREATMENT SPECIFIC TREATMENT SATISFACTION MEASUREMENT

    Nov 1, 2002, 00:00

  • PMD6 MODIFYING COST-EFFECTIVENESS RATIOS TO BE MAXIMALLY COMPARABLE ACROSS MULTIPLE DISEASES-AN APPLICATION OF MANIFOLD THEORY

    Nov 1, 2002, 00:00

  • PIN23 PHARMACOECONOMIC EVALUATION OF ANTIBACTERIALS UTILIZATION IN PRIMARY, SECONDARY AND TERTIARY HOSPITALS IN DEVELOPING ECONOMY

    Nov 1, 2002, 00:00

  • PDB3 INTENSIVE LIFESTYLE CHANGES OR METFORMIN IN OVERWEIGHT, GLUCOSE INTOLERANT PATIENTS- MODELING THE LONG-TERM HEALTH ECONOMICS IMPLICATIONS OF THE DIABETES PREVENTION PROGRAM IN THE FRENCH, GERMAN, AND UK SETTINGS

    Nov 1, 2002, 00:00

  • PCV26 THE HEALTH ECONOMIC IMPLICATIONS OF TREATING ANEMIA IN PATIENTS WITH CONGESTIVE HEART FAILURE

    Nov 1, 2002, 00:00

  • PMH13 STUDY DESCRIPTION AND BASELINE RESULTS OF THE SCHIZOPHRENIA OUTCOMES SURVEY (SOS) OBSERVATIONAL STUDY IN BELGIUM

    Nov 1, 2002, 00:00

  • PES18 VISION RELATED QUALITY OF LIFE OF FRENCH PATIENTS IS AFFECTED BY TOPICAL GLAUCOMA TREATMENT SIDE EFFECTS

    Nov 1, 2002, 00:00

  • PHP20 HARMONIZATION OF HOSPITAL COSTS

    Nov 1, 2002, 00:00

  • POD7 THE IMPACT OF FALLING ON HEALTH CARE UTILIZATION AND COSTS-A COMPARISON OF PROPENSITY SCORING AND TWO-PART MODELS

    Nov 1, 2002, 00:00

  • PCV11 RESOURCE UTILIZATION DURING THE FOUR MONTHS FOLLOWING A DIAGNOSIS OF DEEP VENOUS THROMBOSIS

    Nov 1, 2002, 00:00

  • PCV43 IS THERE ANY RELATIONSHIP BETWEEN COMPLIANCE AND HRQOL IN PATIENTS WITH HEART FAILURE?

    Nov 1, 2002, 00:00

  • PMH16 RECRUITMENT FOR SCHIZOPHRENIA RESEARCH- EXPLORING THE DIFFERENCES BETWEEN COMMUNITY MENTAL HEALTH CENTERS AND NATIONAL ALLIANCE FOR THE MENTALLY ILL

    Nov 1, 2002, 00:00

  • PIN9 PHARMACOECONOMIC ANALYSIS OF COMMUNITY ACQUIRED PNEUMONIA TREATMENT WITH TELITHROMYCIN OR CLARITHROMYCIN

    Nov 1, 2002, 00:00

  • HS3 ECONOMIES OF SCALE IN INTENSIVE CARE UNITS

    Nov 1, 2002, 00:00

  • PCN19 EXAMINING PREFERENCES AND TIMETRADE-OFF UTILITY FOR GEMCITABINE PLUS CISPLATIN IN THE TREATMENT OF BLADDER CANCER-A SURVEY USING DISCRETE CHOICE CONJOINT ANALYSIS IN THE UK

    Nov 1, 2002, 00:00

  • PRK15 A SURVEY ON THE CLINICAL MANAGEMENT OF CMV RISK IN PATIENTS FOLLOWING RENAL TRANSPANTATION IN FRANCE

    Nov 1, 2002, 00:00

  • PDB13 REAL WORLD ADHERENCE BENEFITS FROM COMBINATION PRODUCTS UTILIZED IN DIABETICS- SULFONYLUREAS METFORMIN

    Nov 1, 2002, 00:00

  • PDB4 THE HEALTH-ECONOMIC IMPLICATIONS OF THE 'IRBESARTAN IN DIABETIC NEPHROPATHY TRIAL' (IDNT) IN FRANCE AND BELGIUM

    Nov 1, 2002, 00:00

  • PMH9 ESTIMATING COST-EFFECTIVENESS OF CONCERTA OROS IN ATTENTIONDEFICIT/HYPERACTIVITY DISORDER (ADHD)-ADAPTING THE CANADIAN COORDINATING OFFICE FOR HEALTH TECHNOLOGY ASSESSMENTS PERSPECTIVE

    Nov 1, 2002, 00:00

  • PWM1 HEALTH CARE RESOURCE USE FOR HEAVY MENSTRUAL LOSS

    Nov 1, 2002, 00:00

  • PHP27 HEALTH STATE VALUATIONS IN SUMMARY MEASURES OF POPULATION HEALTH

    Nov 1, 2002, 00:00

  • PCN4 IN THE UK GEMZAR DOUBLET HAS LOWEST TOTAL TREATMENT COSTS FOR NSCLC COMPARED TO FOUR OTHER CHEMOTHERAPY DOUBLETS

    Nov 1, 2002, 00:00

  • PIN27 IMPACT OF SIMPLER HIV-THERAPY ON ADHERENCE AND QUALITY OF LIFE

    Nov 1, 2002, 00:00

  • PCV15 MANAGEMENT EFFECTIVENESS AND COST/UTILITY RATIO IN CHRONIC HEART FAILURE- COMPARISON BETWEEN HEART FAILURE MANAGEMENT PROGRAM DELIVERED BY DAY-HOSPITAL AND USUAL CARE

    Nov 1, 2002, 00:00

  • PMD1 THE NEW METHOD FOR TIME ADJUSTMENT OF THE NUMBER NEEDED TO TREAT AND ITS APPLICATION TO PHARMACOECONOMICS ANALYSIS

    Nov 1, 2002, 00:00

  • UT4 PATIENT-DERIVED UTILITY ESTMATES OF CHRONIC HEPATITIS C BASED ON EQ-5D AND RS SCORES

    Nov 1, 2002, 00:00

  • PGS9 OUTCOMES ANALYSIS OF RABEPRAZOLE (ACIPHEX) USE AT A VETERAN AFFAIRS MEDICAL CENTER

    Nov 1, 2002, 00:00

  • PMH15 SEXUAL DYSFUNCTION AND ANTIPSYCHOTIC DRUG ADHERENCE IN PEOPLE WITH SCHIZOPHRENIA

    Nov 1, 2002, 00:00

  • PIN32 A COMPARISON OF CONJOINT ANALYSIS AND TIME TRADE OFF ELICITED UTILITIES FOR QUALITY OF LIFE STATES ASSOCIATED WITH THE TREATMENT OF GENITAL HERPES

    Nov 1, 2002, 00:00

  • UT6 IMPROVEMENT IN HEALTH UTILITY AMONG RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED WITH ADALIMUMAB (D2E7), A FULLY HUMAN ANTI-TNF MONOCLONAL ANTIBODY

    Nov 1, 2002, 00:00

  • PCV19 TWO METHODS OF ASSESSING COSTS OF PHARMACOLOGICAL TREATMENT ASSOCIATED WITH CHRONIC VENOUS INSUFFICIENCY (CVI) IN POLAND

    Nov 1, 2002, 00:00

  • PIN24 IMPACT OF INFLUENZA VACCINATION ON WORK PRODUCTIVITY IN A COLOMBIAN COMPANY- COSTS AND BENEFITS FOR THE EMPLOYER

    Nov 1, 2002, 00:00

  • PRK2 COSTS OF CHRONIC KIDNEY DISEASE (CKD)- COST AND COMORBIDITY

    Nov 1, 2002, 00:00

  • PCV16 INCIDENCE AND ECONOMIC BURDEN OF DEEP VEIN THROMBOSIS AFTER TOTAL HIP REPLACEMENT IN HONG KONG

    Nov 1, 2002, 00:00

  • PMD15 THE INFLUENCE OF ILLNESS EXPERIENCE ON VALUATION COMPRESSION

    Nov 1, 2002, 00:00

  • PNP1 CHOLINESTERASE INHIBITORS REDUCE INSTITUTIONALIZATION RISK AND MAY REDUCE OVERALL ECONOMIC BURDEN FOR PATIENTS WITH DEMENTIA IN A NATURALISTIC TREATMENT SETTING

    Nov 1, 2002, 00:00

  • WP2 ESTIMATING WILLINGNESS TO PAY FOR DRUGS TO TREAT ADHD-A CONTINGENT VALUATION STUDY IN STUDENTS

    Nov 1, 2002, 00:00

  • PHP11 DESCRIPTIVE AND COMPARATIVE STUDY OF PATIENT-MANAGEMENT BY HOMEOPATHIC GPS VERSUS ALLOPATHIC GPS

    Nov 1, 2002, 00:00

  • PWM6 POST-MENOPAUSAL HORMONE THERAPY- DO HYPERTENSION AND THROMBOPHILIA MATTER?

    Nov 1, 2002, 00:00

  • PAR7 MODELLED COST-EFFECTIVENESS AND COSTUTILITY ANALYSIS OF VARIOUS TREATMENT STRATEGIES IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN IN POLAND

    Nov 1, 2002, 00:00

  • WD2 PRE-TERM PREGNANCY TERMINATIONS FOLLOWING EXPOSURE TO ANTIDEPRESSANTS-A META-ANALYSIS

    Nov 1, 2002, 00:00

  • PWM9 ASSOCIATION BETWEEN PATERNAL EXPOSURE TO SOLVENTS AND FETAL MALFORMATIONS

    Nov 1, 2002, 00:00

  • PMH19 GENDER DIFFERENCES IN PSYCHOACTIVE MEDICATION TREATMENT FOR ATTENTIONDEFICIT/HYPERACTIVITY DISORDER (AD/HD)- RESULTS FROM A POPULATION-BASED STUDY

    Nov 1, 2002, 00:00

  • PGS10 TOWARDS A MULTISTAGE DECISION ANALYSIS FOR THE TREATMENT OF FAECAL INCONTINENCE

    Nov 1, 2002, 00:00

  • PMD7 VALUATION OF INFORMAL CARE-THE OPPORTUNITY COST METHOD APPLIED IN CAREGIVING FOR STROKE AND RHEUMATOID ARTHRITIS PATIENTS

    Nov 1, 2002, 00:00

  • PGS8 META-ANALYSIS OF ESOMEPRAZOLE 40MG AND LANSOPRAZOLE 30MG IN THE HEALING OF REFLUX OESOPHAGITIS

    Nov 1, 2002, 00:00

  • HP3 A RISK-ADJUSTED LEAGUE TABLE OF EXPECTED RETURNS

    Nov 1, 2002, 00:00

  • PHP5 'AUT IDEM'-250 MILLION SAVINGS P. A. FOR STATUARY HEALTH INSURANCE IN GERMANY?

    Nov 1, 2002, 00:00

  • PIN16 INFLUENZA TREATMENT WITH OSELTAMIVIR IN A HIGH RISK POPULATION-A COSTEFFECTIVE OPTION FOR THE HEALTH CARE PAYER

    Nov 1, 2002, 00:00

  • PAR2 THE COST-EFFECTIVENESS ANALYSIS OF CELECOXIB AND NSAIDS WITH GASTROPROTECTIVE AGENTS FOR TREATMENT OF RHEUMATOID ARTHRITIS IN UKRAINE

    Nov 1, 2002, 00:00

  • PES8 LOW VISUAL ACUITY AND BLINDNESS SOCIAL COSTS IN FRANCE

    Nov 1, 2002, 00:00

  • PMD19 A CRITICAL REVIEW OF HEALTH-RELATED PRODUCTIVITY MEASURES

    Nov 1, 2002, 00:00

  • CV1 COST-EFFECTIVENESS OF FONDAPARINUX VS ENOXAPARIN AS PROPHYLAXIS AGAINST VENOUS THROMBOEMBOLISM FOLLOWING ORTHOPAEDIC SURGERY

    Nov 1, 2002, 00:00

  • PHP22 WEBSITES AS TOOLS OF PROMOTING HEALTH IN SOUTH EAST EUROPE

    Nov 1, 2002, 00:00

  • PCV9 OUTCOMES AND COSTS OF THROMBOPROPHYLAXIS WITH LOWMOLECULAR WEIGHT HEPARIN IN ACUTELYILL MEDICAL INPATIENTS

    Nov 1, 2002, 00:00

  • PNP13 QUALITY OF LIFE (QOL) AND PHARMACOECONOMICAL ASPECTS IN PATIENTS WITH SYMPTOMATIC LOCALIZATION-RELATED EPILEPSIES (SLE) IN MOSCOW

    Nov 1, 2002, 00:00

  • MC1 DEVELOPMENT OF A FUNCTIONAL ASSESSMENT IN MIGRAINEURS MEASUREMENT TOOL BASED ON THE WHOS ICIDH2 CLASSIFICATION

    Nov 1, 2002, 00:00

  • PES20 DERIVATION OF SYMPTOMS SCORES AND QOL SCORES FROM CLINICAL DATA IN SEASONAL ALLERGIC CONJUNCTIVITIS

    Nov 1, 2002, 00:00

  • PIN5 COST-EFFECTIVENESS OF DROTRECOGIN ALFA (ACTIVATED) FOR THE TREATMENT OF SEVERE SEPSIS-A CROSS-NATIONAL COMPARISON OF THREE EUROPEAN COUNTRIES

    Nov 1, 2002, 00:00

  • PHP3 IMPROVING PATIENT ACCESS TO INNOVATION-THE NEW BELGIAN REIMBURSEMENT PROCEDURE

    Nov 1, 2002, 00:00

  • PIN10 ECONOMIC EVALUATION DEMONSTRATES THAT MOXIFLOXACIN IV/PO MONOTHERAPY IS COST-EFFECTIVE TO THE SPANISH NATIONAL HEALTHCARE SYSTEM WHEN COMPARED TO IV/PO AMOXICILLIN/CLAVULANATE +/- CLARITHROMYCIN IN THE TREATMENT OF COMMUNITY-ACQUIRED ...

    Nov 1, 2002, 00:00

  • PDB11 TYPE 1 DIABETES, LONG-TERM COMPLICATIONS AND QUALITY OF LIFE MEASURED WITH RAND-36 HEALTH PROFILE MEASURE

    Nov 1, 2002, 00:00

  • PMH21 IMPROVING THE MEASUREMENT PROPERTIES OF THE QUALITY OF LIFE IN DEPRESSION SCALE

    Nov 1, 2002, 00:00

  • PRK13 REGIONAL SIMILARITIES IN IMPROVEMENT AND PERSISTENCE OF SHORT-TERM HEALTH-RELATED QUALITY OF LIFE EFFECT OF TOLTERODINE ON OVERACTIVE BLADDER PATIENTS

    Nov 1, 2002, 00:00

  • PGS2 ECONOMIC BURDEN OF IBS

    Nov 1, 2002, 00:00

  • PIN2 SEVERE SEPSIS- CLINICAL TRIAL VERSUS DAILY PRACTICE.A COST ANALYSIS IN BELGIUM

    Nov 1, 2002, 00:00

  • PHP2 VARIABILITY IN EUROPEAN REIMBURSEMENT SCHEMES FOR ANTIBIOTICS- CONSEQUENCES FOR EUROPEAN SURVEILLANCE OF ANTIBIOTIC CONSUMPTION (ESAC PROJECT)

    Nov 1, 2002, 00:00

  • PES15 USING A DISCRIMINANT FUNCTION TO MODEL THE LONG-TERM VISUAL FIELD CONSEQUENCES OF IOP CONTROL-A CASE STUDY BASED ON A TIMOLOL, LATANOPROST AND TRAVOPROST CLINICAL TRIAL

    Nov 1, 2002, 00:00

  • PES21 IMPACT OF HYDROTHERAPY CARES ON THE QUALITY OF LIFE OF PATIENTS SUFFERING FROM SKIN DISEASES

    Nov 1, 2002, 00:00

  • PHP25 METHODOLOGICAL ISSUES- RESOURCE-BASED ZERO WORK HOUR PROCEDURES IN U.S. PHYSICIANS OFFICES

    Nov 1, 2002, 00:00

  • CP2 THE IMPACT OF VARYING DEGREES OF COMPLIANCE WITH OSTEOPOROSIS MEDICATION ON FRACTURE RATES IN ACTUAL PRACTICE

    Nov 1, 2002, 00:00

  • PHP23 THE CONTRIBUTION OF HEALTH ECONOMICS TO PORTFOLIO MANAGEMENT DECISIONS-A VACCINE INDUSTRY EXAMPLE

    Nov 1, 2002, 00:00

  • PGS7 ANALYSIS OF RESOURCE USE AND COSTS ASSOCIATED WITH MINOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAID) RELATED GASTRO-INTESTINAL (GI) EVENTS

    Nov 1, 2002, 00:00

  • PIN1 THE COSTS OF SEVERE SEPSIS-THE NETHERLANDS, 2000

    Nov 1, 2002, 00:00

  • PDB10 A CROSS-OVER RANDOMISED CONTROLLED TRIAL TO COMPARE PSYCHOLOGICAL BARRIERS TO INSULIN SELF-INJECTION WITH THE INNOLET AND VIAL/SYRINGE

    Nov 1, 2002, 00:00

  • PHP18 ESTIMATING THE ECONOMIC BURDEN OF HOSPITALIZATION DUE TO PATIENT NONADHERENCE IN CANADA

    Nov 1, 2002, 00:00

  • PDB6 RETROSPECTIVE STUDY EVALUATING CLINICAL AND ECONOMIC OUTCOMES OF MONOTHERAPY VERSUS DUAL THERAPY IN DIABETIC PATIENTS IN A COUNTY HEALTH CARE SYSTEM

    Nov 1, 2002, 00:00

  • PHP4 OUT-OF-POCKET PAYMENT IN BELGIUM-AN ANALYSIS IN RELATION TO PATHOLOGY

    Nov 1, 2002, 00:00

  • Abstracts Index

    Nov 1, 2002, 00:00

  • PHP26 CLASSIFICATION AND REGRESSION TREES HELP IN DEVELOPING EMBEDDED EVIDENCEAND CONSENSUS-BASED GUIDELINES

    Nov 1, 2002, 00:00

  • CV3 MULTI-COUNTRY COMPARISON OF HYPERTENSION COSTS FROM HOSPITALIZATIONS AND AMBULATORY CARE

    Nov 1, 2002, 00:00

  • PHP6 DRUG COSTS REGULATION SYSTEM IN THE SLOVAK REPUBLIC

    Nov 1, 2002, 00:00

  • PCV14 ECONOMIC EVALUATION OF A COMPLIANCE PROGRAM IN PATIENTS WITH STATIN THERAPY-DESIGN AND PILOT PHASE OF THE ORBITAL STUDY

    Nov 1, 2002, 00:00

  • PCN20 IS THERE DIFFERENCE BETWEEN GEMCITABINE BASED NSCLC TREATMENT AND OTHER PLATINUM BASED COMBINATIONS FOR RESPONSE RATES AND TOXICITY?

    Nov 1, 2002, 00:00

  • PES6 PATIENT REPORTED OUTCOMES AND HEATH SYSTEM ECONOMIC IMPACT OF A REFORMULATION TO IMPROVE BRIMONIDINE 0.2 PATIENT OUTCOMES

    Nov 1, 2002, 00:00

  • PMD2 THE USE OF DISCRETE CHOICE MODELLING IN THE DESIGN OF CLINICAL TRIALS

    Nov 1, 2002, 00:00

  • PIN26 THE COST EFFECTIVENESS OF SAFE AND APPROPRIATE USE OF INJECTION POLICIES IN HEALTH CARE SETTINGS

    Nov 1, 2002, 00:00

  • PCV22 A PHARMACOECONOMIC EVALUATION OF AGGRESSIVE LIPID-LOWERING THERAPY COMPARED WITH ANGIOPLASTY IN STABLE CORONARY ARTERY DISEASE IN SPAIN

    Nov 1, 2002, 00:00

  • PDB15 USE OF THE PATIENT ANALYSIS TRACKING SYSTEM (PATS) IN ASSESSMENT OF RATIONAL PHARMACOTHERAPY OF DIABETICS IN A BIG HOSPITAL

    Nov 1, 2002, 00:00

  • PES13 RESOURCE UTILIZATION IN PATIENTS SUFFERING FROM ATOPIC DERMATITIS IN GERMANY

    Nov 1, 2002, 00:00

  • DISCLOSURE INFORMATION

    Nov 1, 2002, 00:00

  • POD9 A PHARMACOECONOMIC EVALUATION OF THE USE OF THYROTROPIN-ALFA (THYROGEN) IN THE DETECTION OF THYROID REMNANTS AND WELLDIFFERENTIATED THYROID CANCER IN THE DUTCH HEALTH CARE SETTING

    Nov 1, 2002, 00:00

  • PMH5 A DISCRETE EVENTS MODEL OF LONG-TERM OUTCOMES AND COST OF TREATMENT WITH LONG ACTING RISPERIDONE IN SCHIZOPHRENIA

    Nov 1, 2002, 00:00

  • PRP5 EPIDEMIOLOGICAL STUDY ESTIMATING THE PREVALENCE OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS IN GERMANY

    Nov 1, 2002, 00:00

  • PHP8 AN ECONOMIC MODEL FOR COOPERATION BETWEEN A NOT-FOR-PROFIT HMO AND A PHARMACEUTICAL COMPANY IN A DISEASE MANAGEMENT PROGRAM-TRANSFORMING CONFLICT OF INTERESTS INTO UTILITY MAXIMIZATION

    Nov 1, 2002, 00:00

  • PWM3 SECOND-GENERATION VERSUS FIRSTGENERATION ENDOMETRIAL ABLATION TECHNIQUES IN THE TREATMENT OF DYSFUNCTIONAL UTERINE BLEEDING (DUB)-A REVIEW OF THE LITERATURE

    Nov 1, 2002, 00:00

  • PCV17 COST-EFFECTIVENESS ANALYSIS OF TREATMENTS TO REDUCE CHOLESTEROL CONCENTRATION, BLOOD PRESSURE AND SMOKING FOR THE PREVENTION OF CORONARY HEART DISEASE

    Nov 1, 2002, 00:00

  • PCV46 CORRELATES OF SATISFACTION WITH PAIN CONTROL AMONG CARDIOVASCULAR PATIENTS IN THE US (2001)

    Nov 1, 2002, 00:00

  • PGS13 HEALTH STATE UTILITIES AND WILLINGNESS TO PAY IN GERD PATIENTS WITH HEARTBURN

    Nov 1, 2002, 00:00

  • PCV28 PERSISTENCE WITH ANTIHYPERTENSIVE DRUG TREATMENT-AN EVALUATION BASED ON A BAYESIAN COST-EFFECTIVENESS APPROACH

    Nov 1, 2002, 00:00

  • PNP16 MEDICATION USE IN PATIENTS WITH LOW BACK PAIN- DATA FROM MANAGED CARE

    Nov 1, 2002, 00:00

  • IN2 COST-EFFECTIVENESS (CE) OF SCREENING DONATED BLOOD WITH MINIPOOL NUCLEIC ACID TESTING (NAT) FOR HEPATITIS B VIRUS (HBV), HEPATITIS C VIRUS (HCV), AND HUMAN IMMUNODEFICIENCY VIRUS (HIV)

    Nov 1, 2002, 00:00

  • IN5 ECONOMIC EVALUATION OF A LARGE-SCALE MENINGOCOCCAL C VACCINATION PROGRAM IN THE NETHERLANDS

    Nov 1, 2002, 00:00

  • CC2 RECOMMENDATIONS ON HRQL/UTILITY DATA IN 14 EUROPEAN PHARMACOECONOMIC GUIDELINES

    Nov 1, 2002, 00:00

  • PNP2 ECONOMIC IMPACT OF TREATMENT OF DEMENTIA FOR GERMANY-A PROGNOSIS TO 2050

    Nov 1, 2002, 00:00

  • PRK9 PATIENTS TREATED WITH SERENOA REPENS- EVOLUTION OF THE IPSS SCORES IN TERMS OF IRRITATION AND OBSTRUCTION

    Nov 1, 2002, 00:00

  • PCN11 PROPENSITY ANALYSIS OF EPOETIN USE AND ITS IMPACT ON OVERALL COSTS OF CANCER CARE

    Nov 1, 2002, 00:00

  • PES24 PSORIASIS, QUALITY OF LIFE AND DEPRESSIVE SYMPTOMATOLOGY- FRENCH RESULTS

    Nov 1, 2002, 00:00

  • PHP14 MANAGING THERAPEUTICS NOVELTIES USING A SCIENTIFIC EVIDENCE-BASED METHOD

    Nov 1, 2002, 00:00

  • PCV36 OBESITY AND POTENTIAL COST OFFSETS FROM WEIGHT LOSS-FINDINGS FROM THE SWEDISH MALMO PREVENTION STUDY

    Nov 1, 2002, 00:00

  • HS1 COST-EFFECTIVENESS AND BUDGET IMPACT OF THE SIROLIMUS-ELUTING STENT IN THE STENT ERA

    Nov 1, 2002, 00:00

  • PGS14 CORRELATION BETWEEN DIFFERENT PRODUCTIVITY VARIABLES OBTAINED FROM THE WPAI-GERD QUESTIONNAIRE

    Nov 1, 2002, 00:00

  • PES3 LIFE-LONG SOCIETAL NET VALUE OF GLAUCOMA TREATMENT-A MARKOV MODEL APPROACH

    Nov 1, 2002, 00:00

  • PNP7 ECONOMIC EVALUATION OF LEVETIRACETAM AS ADJUNCTIVE THERAPY IN REFRACTORY EPILEPTIC PATIENTS

    Nov 1, 2002, 00:00

  • PES23 PSORIASIS AND QUALITY OF LIFE SPANISH RESULTS

    Nov 1, 2002, 00:00

  • PRK10 PATIENTS TREATED WITH SERENOA REPENS- EVOLUTION OF THE SCORES SPI AND SF12

    Nov 1, 2002, 00:00

  • PIN28 REVIEW OF QOL AND HRQOL INSTRUMENTS AVAILABLE FOR MEASURING OUTCOME IN HIV/AIDS

    Nov 1, 2002, 00:00

  • PIN14 COST-CONSEQUENCE COMPARISON OF LOPINAVIR/RITONAVIR (LPV/r) VS. NELFINAVIR (NFV) THERAPY IN TREATING ANTIRETROVIRAL NAVE HIV PATIENTS USING CLINICAL TRIAL DATA

    Nov 1, 2002, 00:00

  • PRK11 BPH AND IPSS SCORES EVALUATED AFTER SIX MONTHS ACCORDING TO THE TYPE OF DISEASE MANAGEMENT

    Nov 1, 2002, 00:00

  • PAR1 PHARMACOECONOMIC ANALISIS OF THE TREATMENT WITH LEFLUNOMIDEMETHOTREXATE OR INFLIXIMABMETHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS RESISTANT TO METHOTREXATE

    Nov 1, 2002, 00:00

  • PRP7 HEALTH RELATED QUALITY OF LIFE (HRQOL) IN ASTHMA PATIENTS IN RELATIONSHIP TO ASTHMA SEVERITY DEGREE

    Nov 1, 2002, 00:00

  • HP1 EFFICIENT PRODUCTION OF HEALTH BENEFITS- COST-EFFECTIVENESS EVIDENCE AND UTILISATION OF HEALTH TECHNOLOGY IN THE UK

    Nov 1, 2002, 00:00

  • POD5 EVALUATION OF A PALLIATIVE CARE TEAM ON RESOURCE UTILIZATION IN AN ACUTE CARE SETTING

    Nov 1, 2002, 00:00

  • PES4 A DISEASE SEVERITY STAGING SYSTEM FOR MEASURING THE COST OF GLAUCOMA PROGRESSION IN EUROPE

    Nov 1, 2002, 00:00

  • PMD18 THE INTERNATIONAL HEALTH-RELATED QUALITY OF LIFE OUTCOMES DATABASE (IQOD) PROGRAMME-WHQ AND PGWBI DATABASES- REFERENCES VALUES FOR CROSSCULTURAL COMPARISONS

    Nov 1, 2002, 00:00

  • PRK12 APPLYING CONJOINT ANALYSIS TO THE VALUATION OF OVERACTIVE BLADDER DRUGEFFICACY VARIABLES AND SIDE EFFECTS

    Nov 1, 2002, 00:00

  • POD4 INCIDENCE AND PREVENTION OF NEEDLE STICK INJURY RELATED TO SUBCUTANEOUS INJECTION- EXAMPLE OF THE IMPACT OF A LOW MOLECULAR WEIGHT HEPARIN SAFETY SYRINGE

    Nov 1, 2002, 00:00

  • PCN15 ANEMIA RESULTS IN INCREASED UTILIZATION IN CANCER PATIENTS

    Nov 1, 2002, 00:00

  • PMH22 ADHD HAS A SIGNIFICANT BURDEN UPON THE INDIVIDUAL, FAMILY AND SOCIETY IN EUROPE

    Nov 1, 2002, 00:00

  • PGS6 COST COMPARISON OF ESOMEPRAZOLE BASED AND OMEPRAZOLE BASED HELICOBACTER PYLORI ERADICATION STRATEGIES IN DUODENAL ULCER DISEASE IN GREECE

    Nov 1, 2002, 00:00

  • PHP16 GENERIC DRUG PRICES ARE TYPICALLY HIGHER IN CANADA THAN IN THE UNITED STATES

    Nov 1, 2002, 00:00

  • PMD10 ISPOR QUALITY OF LIFE SPECIAL INTEREST GROUP TRANSLATION AND CULTURAL ADAPTATION- PROGRESS ON THE DEVELOPMENT OF PRINCIPLES OF BEST PRACTICE

    Nov 1, 2002, 00:00

  • PCV58 RANDOMIZED CONTROLLED INTERVENTION IN CARDIOVASCULAR DRUG TREATMENT IN NURSING HOMES

    Nov 1, 2002, 00:00

  • HS2 COST-EFFECTIVENESS OF LEUKODEPLETION IN MAJOR CARDIAC SURGERY

    Nov 1, 2002, 00:00

  • PHP1 ASSESSMENT OF PROPOSED GUIDELINES FOR PHARMACOECONOMIC SUBMISSIONS IN GREECE- OVERVIEW AND IMPLEMENTATION PROBLEMS

    Nov 1, 2002, 00:00

  • CN1 A STOCHASTIC ECONOMIC EVALUATION OF LETROZOLE VERSUS TAMOXIFEN AS A FIRST-LINE HORMONAL THERAPY FOR ADVANCED BREAST CANCER IN POSTMENOPAUSAL PATIENTS IN GERMANY

    Nov 1, 2002, 00:00

  • PMD13 THE RELEVANCE OF QUANTITY AND QUALITY OF LIFE-YEARS AFTER TREATMENT IN PRIORITIZING BETWEEN DIFFERENT PATIENTS

    Nov 1, 2002, 00:00

  • PCV34 COST-EFFECTIVENESS OF PATHOGEN INACTIVATION FOR PLATELET TRANSFUSIONS IN DUTCH CARDIAC SURGERY

    Nov 1, 2002, 00:00

  • PCV7 ECONOMIC EVALUATION OF THE ATORVASTATIN VERSUS REVASCULARIZATION TREATMENT STUDY (AVERT)-AN ITALIAN CUSTOMIZATION

    Nov 1, 2002, 00:00

  • PGS11 IMPACT OF IBS ON QUALITY OF LIFE AND PSYCHOLOGICAL WELL-BEING IN PATIENTS AND RELATIVES

    Nov 1, 2002, 00:00

  • PCV13 COST OF MANAGING UNSTABLE ANGINA PATIENTS OVER A NINE-MONTH PERIOD-A EUROPEAN APPROACH

    Nov 1, 2002, 00:00

  • PCV55 SMOKING DEPENDENCY-AUDIT CARRIED OUT AMONG THE UNDER 25 GROUP

    Nov 1, 2002, 00:00

  • CN3 IMMUNOTHERAPY WITH AUTOLOGOUS TUMOR CELL-BCG VACCINE (ONCOVAX) IN PATIENTS WITH STAGE II COLON CANCER- MEDICAL AND ECONOMIC BENEFITS

    Nov 1, 2002, 00:00

  • WD3 PATIENT PREFERENCE AND WILLINGNESS-TO-PAY IN FIVE EUROPEAN COUNTRIES FOR HUMALOG MIX25 COMPARED TO HUMULIN 30/70 FOR THE TREATMENT OF TYPE 2 DIABETES

    Nov 1, 2002, 00:00

  • PMD11 A DALY IS A QALY-OR IS IT?

    Nov 1, 2002, 00:00

  • PMH6 DIRECT MEDICAL COSTS FOR TREATMENT OF PATIENTS EXPERIENCING BIPOLAR DISORDER EPISODES IN THE UK

    Nov 1, 2002, 00:00

  • PGS15 FORMULARY CONVERSION OF PROTON PUMP INHIBITORS- MONITORING FOR POTENTIAL DRUG INTERACTION

    Nov 1, 2002, 00:00

  • PCN6 ECONOMICAL EVALUATION OF RALTITREXED VERSUS FLUOROURACIL PLUS LEUCOVORIN (5-FU LV) FOR TREATMENT OF ADVANCED COLORECTAL CANCER

    Nov 1, 2002, 00:00

  • PCV18 SOCIOECONOMIC RELEVANCE OF TREATMENT OF CHRONIC HEART FAILURE STAGE NYHA II WITH CRATAEGUS EXTRACT WS 1442- TWO-YEAR-RESULTS OF A PROSPECTIVE PHARMACOECONOMIC STUDY

    Nov 1, 2002, 00:00

  • CC3 MEASURING POPULATION HEALTH FOR 191 COUNTRIES-WHO METHODS AND RESULTS

    Nov 1, 2002, 00:00

  • PDB9 SELF-ASSESSMENT OF DIABETES CONTROL- ACCURACY OF PATIENTS PERCEPTIONS

    Nov 1, 2002, 00:00

  • PCV35 COSTS OF STROKE-A COMPARISON OF REGULAR CARE AND THREE EXPERIMENTAL STROKE SERVICES IN THE NETHERLANDS

    Nov 1, 2002, 00:00

  • PIN11 COMPARING HOSPITAL COSTS BETWEEN LINEZOLID AND VANCOMYCIN IN THE TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCAL SPECIES (MRSS) INFECTIONS-A RANDOMIZED MULTI-CENTER CLINICAL TRIAL

    Nov 1, 2002, 00:00

  • WP1 WILLINGNESS TO PAY FOR PHARMACISTPROVIDED MENOPAUSE AND HORMONE REPLACEMENT THERAPY CONSULTATIONS

    Nov 1, 2002, 00:00

  • CP3 CLAIMS BASED MEASURES OF DRUG TAKING COMPLIANCE AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA- FEASIBILITY AND PREDICTIVE UTILITY

    Nov 1, 2002, 00:00

  • PMH17 TREATMENT SATISFACTION AND COMPLIANCE WITH RISPERIDONE USE IN PATIENTS WITH BIPOLAR DISORDER

    Nov 1, 2002, 00:00

  • PIN8 LENGTH OF STAY AND ANTIFUNGAL TREATMENTS COSTS IN PATIENTS WITH SYSTEMIC MYCOSIS- DESCRIPTION AND ASSOCIATED FACTORS

    Nov 1, 2002, 00:00

  • PGS1 EMPLOYMENT LOSSES RELATED TO INFLAMMATORY BOWEL DISEASE IN THE UNITED STATES- RESULTS FROM THE NATIONAL INTERVIEW SURVEY

    Nov 1, 2002, 00:00

  • PCV49 THE INFLUENCE OF COPAYMENTS ON THE DEMAND FOR DRUGS WITH THERAPEUTIC COMPETITORS-THE STATINS

    Nov 1, 2002, 00:00

  • PMD8 TRENDS IN DATA SOURCES USED FOR ECONOMIC EVALUATION

    Nov 1, 2002, 00:00

  • OD2 LONG-ACTING RISPERIDONE IN SCHIZOPHRENIC PATIENTS COMPARED WITH ORAL OLANZAPINE AND HALOPERIDOL DECANOATE-A COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2002, 00:00

  • PHP12 SELF-REPORTED PATIENT EXPERIENCE DATA, PROVIDED TO PHYSICIANS AT THE POINT-OFCARE, OFFERS AN IMPORTANT COMPLEMENT TO TRADITIONAL EFFICACY DATA AND ENABLES THE DERIVATION OF PRACTICEWIDE TREATMENT GUIDELINES

    Nov 1, 2002, 00:00

  • PCV47 THE ASSESSMENT OF THE INFLUENCE OF AN EDUCATIONAL INTERVENTION ON PATIENT IMPORTANT OUTCOMES INCLUDING HEALTH RELATED QUALITY OF LIFE (HRQOL) AND MORTALITY USING A TIME-TO-EVENT SURVIVAL ANALYSIS IN PATIENTS WITH HEART FAILURE

    Nov 1, 2002, 00:00

  • PIN18 RELEVANCE OF COMPLICATIONS AS COST DRIVERS OF VARICELLA

    Nov 1, 2002, 00:00

  • PCV12 COST-EFFECTIVENES OF ENOXAPARIN AS THROMBOPROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS IN BRAZIL

    Nov 1, 2002, 00:00

  • PMH12 PATIENT AND DISEASE CHARACTERISTICS IN SCHIZOPHRENIA OUTPATIENTS AND INPATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY- RESULTS FROM THE GEO OBSERVATIONAL STUDY

    Nov 1, 2002, 00:00

  • PCN7 MAJOR DETERMINANTS OF COST IN ADVANCED NON-SMALL-CELL LUNG CANCER CHEMOTHERAPY REGIMES IN FRANCE

    Nov 1, 2002, 00:00

  • PHP28 ECONOMIC STUDY OF MALNUTRITION IN ELDERLY PATIENTS LIVING IN THE COMMUNITY- USE OF PROPENSITY SCORE TO ANALYZE OBSERVATIONAL DATA

    Nov 1, 2002, 00:00

  • PES19 INITIAL DEVELOPMENT AND VALIDATION OF THE EYE ALLERGY PATIENT IMPACT QUESTIONNAIRE (EAPIQ)

    Nov 1, 2002, 00:00

  • PCN2 COST-EFFECTIVENESS OF NEW CERVICAL CANCER SCREENING TECHNOLOGIES-A GERMAN HEALTH TECHNOLOGY ASSESSMENT AND DECISION-ANALYSIS

    Nov 1, 2002, 00:00

  • PMD9 BEHAVIOURAL ECONOMICS-THE IMPORTANCE OF ABSOLUTE AND RELATIVE HEALTH OUTCOMES

    Nov 1, 2002, 00:00

  • PCN13 GEMZAR RETROSPECTIVE ECONOMIC ANALYSIS OF CLINICAL TRIALS (GREAT) IN THE TREATMENT OF NON-SMALL-CELL LUNG CANCER-A MULTI-COUNTRY COSTMINIMISATION ANALYSIS

    Nov 1, 2002, 00:00

  • MD1 THE EQUITY-EFFICIENCY TRADEOFF-WHAT IS THE SOCIAL INTERPRETATION OF EQUITY?

    Nov 1, 2002, 00:00

  • PMH25 CORRESPONDENCE COURSE FOR GPS IMPROVED QUALITY AND PERSISTENCY OF ANTI-DEPRESSIVE THERAPY (RESULTS FROM THE IMPROVE-D STUDY)

    Nov 1, 2002, 00:00

  • PES22 IMPACT OF CHILDREN QUALITY OF LIFE

    Nov 1, 2002, 00:00

  • PCN9 COST-EFFICACY OF ZOLEDRONIC 4MG ACID VS. PAMIDRONATE 90MG IN THE TREATMENT OF HYPERCALCEMIA OF MALIGNACY (HCM)

    Nov 1, 2002, 00:00

  • PIN29 PSYCHOMETRIC PROPERTIES OF THE MODIFIED VIH-47 IN A THERAPEUTIC TRIAL EVALUATING THE IMPACT OF AN EDUCATIONAL PROGRAM IN HIV PATIENTS

    Nov 1, 2002, 00:00

  • PCN21 CANCER CHEMOTHERAPY AT HOME- FEASIBILITY, PATIENT OUTCOMES, AND HEALTHCARE SYSTEM IMPLICATIONS

    Nov 1, 2002, 00:00

  • PES26 HEALTH STATE UTILITIES IN PATIENTS WITH DERMATOLOGICAL PROBLEMS-A POPULATION STUDY

    Nov 1, 2002, 00:00

  • PRP10 A DISEASE MANAGEMENT PROGRAM IN FRANCE- LESSONS FROM THE RESALIS EXPERIMENT 18 MONTHS BEFORE AND 12 MONTHS AFTER PUBLIC HEALTH INTERVENTIONS

    Nov 1, 2002, 00:00

  • POD1 AN ECONOMIC EVALUATION OF NOVOSEVEN IN THE MANAGEMENT OF HAEMOPHILIA PATIENTS WITH INHIBITORS IN SLOVAKIA

    Nov 1, 2002, 00:00

  • PWM2 COST ANALYSIS OF IVF TREATMENT WITH INJECTION DEVICE VS THE TRADITIONAL SYRINGE AND NEEDLE

    Nov 1, 2002, 00:00

  • PCV38 LIPID LOWERING MEDICATIONS FOLLOWING CORONARY REVASCULARIZATION PROCEDURES

    Nov 1, 2002, 00:00

  • PCV6 THE COST COMPARISON OF CARDIOVERSION AND ANTIARRHYTHMIC THERAPY IN NONVALVULAR CHRONIC ATRIAL FIBRILLATION

    Nov 1, 2002, 00:00

  • PCV20 A COST EFFECTIVENESS ANALYSIS OF SPIRONOLACTONE IN THE MANAGEMENT OF PATIENTS WITH SEVERE CHRONIC HEART FAILURE (CHF) IN THE IRISH HEALTHCARE SETTING

    Nov 1, 2002, 00:00

  • PIN30 FURTHER DEVELOPMENT OF THE INFLUENZA DAILY DISRUPTION QUESTIONNAIRE

    Nov 1, 2002, 00:00

  • PIN15 ECONOMIC BURDEN OF CHRONIC HEPATITIS B VIRUS INFECTION AND POTENTIAL COST SAVINGS WITH LAMIVUDINE

    Nov 1, 2002, 00:00

  • PES1 COST OF ILLNESS OF GLAUCOMA IN CANADA- ANALYSES BASED ON VISUAL FIELD MEASUREMENTS AND PHYSICIANS ASSESSMENT

    Nov 1, 2002, 00:00

  • UT1 36 INTO 1 DOESNT GO

    Nov 1, 2002, 00:00

  • PDB14 MEDICAID MANAGED CARE QUALITY AMONG BLACK AND WHITE ADULTS WITH DIABETES MELLITUS

    Nov 1, 2002, 00:00

  • PRP9 EVALUATION OF A DISEASE MANAGEMENT PROGRAM (DMP) FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN GERMANY- PRELIMINARY ASSESSMENT OF EFFECTIVENESS OF COMPOUNDS

    Nov 1, 2002, 00:00

  • PES5 COST-UTILITY ANALYSIS OF TIMOLOL VERSUS LATANOPROST VERSUS TRAVOPROST IN THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION

    Nov 1, 2002, 00:00

  • PMH1 THE HEALTH CARE COSTS OF SCHIZOPHRENIA IN AUSTRALIA- 18-MONTH FOLLOW-UP RESULTS

    Nov 1, 2002, 00:00

  • PGS3 HEALTH CARE RESOURCE UTILIZATION AND COSTS OF TREATING NSAID-ASSOCIATED GASTROINTESTINAL TOXICITY IN JAPAN- FEASIBILITY OF A DELPHI-PANEL APPROACH IN JAPAN

    Nov 1, 2002, 00:00

  • PNP12 PHYSICIAN PREFERENCE FOR ANTIEPILEPTIC DRUG CONCENTRATION TESTING

    Nov 1, 2002, 00:00

  • PNP15 EVALUATION OF THE RELATIONSHIP BETWEEN EPILEPSY SEVERITY AND UTILITY

    Nov 1, 2002, 00:00

  • PCV24 COST-EFFECTIVENSS OF ANTICOAGULATION MANAGEMENT IN TWO MODELS OF CARE

    Nov 1, 2002, 00:00

  • PMD4 WHEN CAN MISSING DATA BE CONSIDERED MISSING AT RANDOM (MAR) IN SUBSTANCE ABUSE TREATMENT OUTCOMES RESEARCH?

    Nov 1, 2002, 00:00

  • PCN5 COMPARING THE COST-EFFECTIVENESS OF FRONT-LOADED DARBEPOETIN ALFA WITH EPOETIN ALFA FOR ANEMIA MANAGEMENT IN CHEMOTHERAPY-TREATED CANCER PATIENTS IN UNITED STATES

    Nov 1, 2002, 00:00

  • PES25 ASSESSMENT OF THE DERMATOLOGIC LIFE QUALITY INDEX (DLQI) IN CHRONIC IDIOPATHIC URTICARIA

    Nov 1, 2002, 00:00

  • PRK14 PREVALENCE OF APPROPRIATE URINARY INCONTINENCE EVALUATIONS IN TEXAS NURSING HOME FACILITIES

    Nov 1, 2002, 00:00

  • PRK1 ASSESSING PROVIDER TIME FOR ANAEMIA MANAGEMENT OF DIALYSIS PATIENTS USING TIME MOTION METHODS-A MULTI-CENTRE OBSERVATIONAL STUDY IN EUROPE

    Nov 1, 2002, 00:00

  • OD3 STOCHASTIC COST-EFFECTIVENESS ANALYSIS OF CHRONIC VENOUS LEG ULCERS-THE CASE OF PROMOGRAN IN A SWEDISH HEALTH CARE SETTING

    Nov 1, 2002, 00:00

  • PMH20 THE EFFECTS OF ETHNICITY AND ANTIPSYCHOTIC AGENT ON MEDICATION ADHERENCE IN A MEDICAID POPULATION

    Nov 1, 2002, 00:00

  • IN3 METHODS FOR ASSESSING COSTS AND EFFECTS OF ANTIRETROVIRAL THERAPIES IN HIV-THE IMPACT OF USING AN EXTENDED STUDY PERIOD

    Nov 1, 2002, 00:00

  • POD3 JOINT RECOVERY IN HIP AND KNEE REPLACEMENT-A COST-EFFECTIVE APPROACH

    Nov 1, 2002, 00:00

  • PHP12 INFLUENCING PRESCRIBING IN ENGLISH PRIMARY CARE- FINDINGS FROM THE MANMED SURVEY

    Nov 1, 2002, 00:00

  • PGS5 A COST-EFFECTIVENESS ANALYSIS OF ESOMEPRAZOLE VS. OMEPRAZOLE IN THE ACUTE TREATMENT OF PATIENTS WITH REFLUX OESOPHAGITIS IN GREECE

    Nov 1, 2002, 00:00

  • PHP9 RISK SHARING IN A STATE FUNDED HEALTH SERVICE- OUTCOMES GUARANTEE PROJECT

    Nov 1, 2002, 00:00

  • PCV29 THE COST-EFFECTIVENESS OF DIAGNOSTIC STRATEGIES WITH ANGIOGRAPHY AND/OR DUPLEX SCANNING FOR AORTOILIAC AND FEMOROPOPLITEAL ARTERIAL DISEASE

    Nov 1, 2002, 00:00

  • PMD5 VALUATION OF NEW DRUG APPLICATIONS OF PHARMACEUTICAL COMPANIES USING COMPOUND OPTION MODELS

    Nov 1, 2002, 00:00

  • PIN6 COST-EFFECTIVENESS ANALYSIS OF LINEZOLID VERSUS TEICOPLANIN IN THE TREATMENT OF INFECTIONS CAUSED BY GRAM-POSITIVE BACTERIA IN SPAIN

    Nov 1, 2002, 00:00

  • PHP7 MODELLING, ECONOMIC EVALUATIONS, AND THE DEVELOPMENT OF CLINICAL PRACTICE GUIDELINES-A SURVEY OF 38 GUIDELINES IN THE NETHERLANDS

    Nov 1, 2002, 00:00

  • POD6 ELECTRONIC IMPLEMENTION OF AN APPROVED TABLET SPLITTING GUIDE WITH PROVIDER ORDER ENTRY-ASSOCIATED COST SAVINGS

    Nov 1, 2002, 00:00

  • PCV42 UNCERTAINTIES IN COST-EFFECTIVENESS EVALUATION OF CAROTID ANGIOPLASTY AND STENTING

    Nov 1, 2002, 00:00

  • PIN25 VACCINATION IN HEALTHY WORKING ADULTS-WHAT RETURN ON INVESTMENT FOR COMPANIES? AN INTERNATIONAL PERSPECTIVE

    Nov 1, 2002, 00:00

  • PES17 PSORIASIS AND DEPRESSIVE SYMPTOMATOLOGY

    Nov 1, 2002, 00:00

  • PMH2 ANTIPSYCHOTIC USE PATTERNS AND HEALTHCARE COSTS FOR INDIVIDUALS WITH SCHIZOPHRENIA TREATED WITH HALOPERIDOL, OLANZAPINE OR RISPERIDONE IN A MEDICAID POPULATION

    Nov 1, 2002, 00:00

  • PIN35 VARICELLA VACCINATION OF PRE-SCHOOL CHILDREN- DETERMINING OPTIMAL COVERAGE LEVELS

    Nov 1, 2002, 00:00

  • PCN4 ONCE-PER-CYCLE FIXED-DOSE ADMINISTRATION OF PEGFILGRASTIM REDUCED RESOURCE UTILIZATION AND COSTS COMPARED WITH DAILY FILGRASTIM IN THE PREVENTION OF CHEMOTHERAPYINDUCED NEUTROPENIA

    Nov 1, 2002, 00:00

  • PCV45 DETERMINANTS OF FIRST-YEAR QUALITY OF LIFE (QOL) AFTER SURGERY-INTERIM ANALYSIS OF A RANDOMISED TRIAL WITH LAPBAND-SURGERY AND VERTICAL BANDED GASTROPLASTY (VBG)

    Nov 1, 2002, 00:00

  • PCV10 COST OF UNCONTROLLED HYPERTENSION IN CANADA

    Nov 1, 2002, 00:00

  • PMD3 RELEVANCE OF PATIENT REPORTED OUTCOMES FOR CHRONIC PAIN PATIENTS- THE ROLE OF SATISFACTION WITH ANALGESIC MEDICATION AND APPLICATION FORM

    Nov 1, 2002, 00:00

  • PDB8 TYPE-2 DIABETES AND BODY MASS INDEX (BMI)-WHAT CAN WE LEARN FROM A LONGITUDINAL DATABASE STUDY?

    Nov 1, 2002, 00:00

  • OD1 THE COST-EFFECTIVENESS OF RALOXIFENE COMPARED WITH NO DRUG THERAPY FOR THE PREVENTION OF OSTEOPOROTIC FRACTURES WHEN HRT IS INAPPROPRIATE- THE CASE OF AUSTRALIA

    Nov 1, 2002, 00:00

  • PMH3 A COST-EFFECTIVENESS COMPARISON OF OLANZAPINE AND RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA IN ITALY

    Nov 1, 2002, 00:00

  • PCV39 A REVIEW OF THE PHARMACOTHERAPEUTIC MANAGEMENT OF PULMONARY ARTERIAL HYPERTENSION

    Nov 1, 2002, 00:00

  • PMH23 ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)-A RECOGNISED DISORDER FOR CHILDREN IN EUROPE

    Nov 1, 2002, 00:00

  • MD6 WHAT IS 'TIME' IN TIME PREFERENCE STUDIES?

    Nov 1, 2002, 00:00

  • PES2 MEDICAL PREDICTIVE FACTORS OF GLAUCOMA TREATMENT COSTS IN FRANCE

    Nov 1, 2002, 00:00

  • HP2 HEALTH ECONOMIC EDUCATION IN ALLOCATION DECISIONS-A PRE-TEST POST-TEST STUDY

    Nov 1, 2002, 00:00

  • PCV27 COMPARING RESOURCE USE INTENSITY IN THREE POPULATIONS WITH ATHEROTHROMBOSIS

    Nov 1, 2002, 00:00

  • PIN20 THE COST-EFFECTIVENESS OF ANTIRETROVIRAL REGIMENS CONTAINING PROTEASE INHIBITORS (PIS) OR NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTI) IN THE TREATMENT OF HIV-INFACTED INDIVIDUALS IN POLAND

    Nov 1, 2002, 00:00

  • PWM8 ASSOCIATION BETWEEN PATERNAL EXPOSURE TO SOLVENTS AND SPONTANEOUS ABORTIONS

    Nov 1, 2002, 00:00

  • PES7 COST-UTILITY OF VITAMINS FOR THE TREATMENT OF MACULAR DEGENERATION

    Nov 1, 2002, 00:00

  • PAR3 VARIATION IN RESOURCE UTILIZATION AND TREATMENT COSTS FOR RHEUMATOID ARTHRITIS (RA) ACROSS 5 COUNTRIES IN AN ADALIMUMAB (D2E7) CLINICAL TRIAL

    Nov 1, 2002, 00:00

  • CV2 ESTIMATION OF EXPENDITURES FOR CORONARY HEART DISEASE (CHD) IN GERMANY

    Nov 1, 2002, 00:00
  • «
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168 (current)
  • 169
  • 170
  • »